Application of physiologically based pharmacokinetic modeling to understand real-world outcomes in patients receiving imatinib for chronic myeloid leukemia.

Adattini, Josephine A; Adiwidjaja, Jeffry; Gross, Annette S; McLachlan, Andrew J

Adattini, Josephine A; Adiwidjaja, Jeffry; Gross, Annette S; McLachlan, Andrew J.

Afiliação

Adattini JA; Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
Adiwidjaja J; Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
Gross AS; Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
McLachlan AJ; Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline R&D, Sydney, Australia.

Pharmacol Res Perspect ; 11(4): e01082, 2023 Aug.

Article em En | MEDLINE | ID: mdl-37417254

Assuntos

Leucemia Mielogênica Crônica BCR-ABL Positiva; Humanos; Mesilato de Imatinib/efeitos adversos; Mesilato de Imatinib/farmacocinética; Citocromo P-450 CYP2C8; Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico; Citocromo P-450 CYP3A

Palavras-chave

adverse drug reactions; drug interactions; early molecular response; exposure-response; imatinib; physiologically based pharmacokinetic (PBPK); simulation

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google